Big 3 PBMs reaped $7.3B from generic specialty drug markups
Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
FTC: Big 3 PBMs generated $7.3B from specialty generic drug markups
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal Trade Commission (FTC) uncovered in its second interim staff report rele | The FTC released its second interim staff report Tuesday during Chair Lina Khan's final open commission meeting,
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
Andrew Witty, UnitedHealth CEO, said the move will remove an excuse other players use to blame Optum Rx for high drug costs.
FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts ...
A Missouri lawmaker is putting the high price of medication under the microscope. “My biggest issue is these PBMs, and what ...
Futurism on MSN4h
Insurance Company Where CEO Was Assassinated Jacking Up Cost of Cancer Drugs by "Thousands of Percent," Government FindsUnitedHealthcare's legal drug dealing arm is, according to the government, massively marking up the cost of life-saving ...
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback